Clinical Trials
99 trialsTherapeutic RSK1 Targeting in Myelofibrosis
Washington University School of Medicine
TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea
Vanderbilt-Ingram Cancer Center
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Prelude Therapeutics
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Newave Pharmaceutical Inc
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
Stanford University
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Safety and Tolerability of ZE74-0282 in Healthy Volunteers
Eilean Therapeutics
Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers
Eilean Therapeutics
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
University of Alabama at Birmingham
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
LIMBER
Incyte Corporation
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
City of Hope Medical Center
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms
Dana-Farber Cancer Institute
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies
M.D. Anderson Cancer Center
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
Dana-Farber Cancer Institute
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
University of Chicago
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant
City of Hope Medical Center
Q702 for the Treatment of Patients With Hematologic Malignancies
Mayo Clinic
A Study of GLB-001 in Patients With Myeloid Malignancies
Hangzhou GluBio Pharmaceutical Co., Ltd.
Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis
AbbVie
Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza
American Regent, Inc.
Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)
University of Virginia
TREG108
Cellenkos, Inc.
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
Icahn School of Medicine at Mount Sinai
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
AbbVie
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
Epigenetix, Inc.
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
Astex Pharmaceuticals, Inc.
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
Fox Chase Cancer Center
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
FluBuATG
Dartmouth-Hitchcock Medical Center
Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis
AbbVie
CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms
Herlev Hospital
A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia
Lynk Pharmaceuticals Co., Ltd
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
Prelude Therapeutics
MPN-RC 118 AVID200 in Myelofibrosis
Icahn School of Medicine at Mount Sinai
Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis
Roswell Park Cancer Institute
Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis
Taiga Biotechnologies, Inc.
HaploOnly
University of Rochester
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Medigene AG
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
H. Lee Moffitt Cancer Center and Research Institute
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
Study of Select Combinations in Adults With Myelofibrosis
Novartis
USBTXA127CBT
Tarix Pharmaceuticals
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
Case Comprehensive Cancer Center
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
Daiichi Sankyo